FORM PTO-1390 (Modified) (REV 11-2000) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE

TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371

ATTORNEY'S DOCKET NUMBER	U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR)
8830-14	10/030573

INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/GB00/03343	September 1, 2000	September 3, 1999

TITLE OF INVENTION
Sealant For Vascular Prostheses

APPLICANT(S) FOR DO/EO/US
Karen Anne Kelso

Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:

1. ☒ This is a **FIRST** submission of items concerning a filing under 35 U.S.C. 371.
2. ☐ This is a **SECOND** or **SUBSEQUENT** submission of items concerning a filing under 35 U.S.C. 371.
3. ☒ This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include itens (5), (6), (9) and (24) indicated below.
4. ☒ The US has been elected by the expiration of 19 months from the priority date (Article 31).
5. ☒ A copy of the International Application as filed (35 U.S.C. 371 (c) (2))
   a. ☐ is attached hereto (required only if not communicated by the International Bureau).
   b. ☒ has been communicated by the International Bureau.
   c. ☐ is not required, as the application was filed in the United States Receiving Office (RO/US).
6. ☐ An English language translation of the International Application as filed (35 U.S.C. 371(c)(2)).
   a. ☐ is attached hereto.
   b. ☐ has been previously submitted under 35 U.S.C. 154(d)(4).
7. ☒ Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371 (c)(3))
   a. ☐ are attached hereto (required only if not communicated by the International Bureau).
   b. ☐ have been communicated by the International Bureau.
   c. ☐ have not been made; however, the time limit for making such amendments has NOT expired.
   d. ☒ have not been made and will not be made.
8. ☐ An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).
9. ☒ An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).
10. ☐ An English language translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371 (c)(5)).
11. ☒ A copy of the International Preliminary Examination Report (PCT/IPEA/409).
12. ☐ A copy of the International Search Report (PCT/ISA/210).

Items 13 to 20 below concern document(s) or information included:

13. ☐ An Information Disclosure Statement under 37 CFR 1.97 and 1.98.
14. ☒ An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.
15. ☒ A **FIRST** preliminary amendment.
16. ☐ A **SECOND** or **SUBSEQUENT** preliminary amendment.
17. ☐ A substitute specification.
18. ☐ A change of power of attorney and/or address letter.
19. ☐ A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.
20. ☐ A second copy of the published international application under 35 U.S.C. 154(d)(4).
21. ☐ A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).
22. ☒ Certificate of Mailing by Express Mail **EL 813789677 US**
23. ☒ Other items or information: **International Application as published with International Search Report**

U.S. APPLICATION NO. (IF KNOWN, SEE 37 CFR	INTERNATIONAL APPLICATION NO.	ATTORNEY'S DOCKET NUMBER
10/030573	PCT/GB00/03343	8830-14

24. The following fees are submitted:.

BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) - (5)) :

		CALCULATIONS PTO USE ONLY
☐	Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO **$1040.00**	
☒	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO **$890.00**	
☐	International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO **$740.00**	
☐	International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4) **$710.00**	
☐	International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) **$100.00**	
	ENTER APPROPRIATE BASIC FEE AMOUNT =	**$890.00**
	Surcharge of **$130.00** for furnishing the oath or declaration later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (e)).	**$0.00**

CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	15 - 20 =	0	x $18.00	**$0.00**
Independent claims	3 - 3 =	0	x $84.00	**$0.00**
Multiple Dependent Claims **(check if applicable)**.			☐	**$0.00**
		TOTAL OF ABOVE CALCULATIONS =		**$890.00**
☐	Applicant claims small entity status. See 37 CFR 1.27). The fees indicated above are reduced by 1/2.			**$0.00**
		SUBTOTAL =		**$890.00**
	Processing fee of **$130.00** for furnishing the English translation later than ☐ 20 ☐ 30 months from the earliest claimed priority date (37 CFR 1.492 (f)). +			**$0.00**
		TOTAL NATIONAL FEE =		**$890.00**
	Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31) **(check if applicable).** ☒			**$40.00**
		TOTAL FEES ENCLOSED =		**$930.00**
			Amount to be: refunded	$
			charged	$

a. ☒ A check in the amount of **$930.00** to cover the above fees is enclosed.

b. ☐ Please charge my Deposit Account No. _____ in the amount of _____ to cover the above fees. A duplicate copy of this sheet is enclosed.

c. ☒ The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. **05-0573** A duplicate copy of this sheet is enclosed.

d. ☐ Fees are to be charged to a credit card. **WARNING:** Information on this form may become public. **Credit card information should not be included on this form.** Provide credit card information and authorization on PTO-2038.

NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.

SEND ALL CORRESPONDENCE TO:

DANIEL A. MONACO
Drinker Biddle & Reath LLP
One Logan Square
18th and Cherry Streets
Philadelphia, Pennsylvania 19103-6996
(215) 988-3312
(215) 988-2757 Fax



SIGNATURE

DANIEL A. MONACO
NAME

30,480
REGISTRATION NUMBER

JANUARY 2, 2001
DATE

PATENT

Attorney Docket No.: 8830-14

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re:	Patent application of Karen Anne Kelso	:	
		:	Group Art Unit:
Serial No.:	not yet assigned (International Application: PCT/GB00/03343)	:	
Filed:	herewith (International Application: Sept. 1, 2000)	:	Examiner:
For:	SEALANT FOR VASCULAR PROTHESES	:	

PRELIMINARY AMENDMENT

Commissioner for Patents
Washington, D.C. 20231
Sir:

Kindly amend the above-identified application, without prejudice, in advance of calculating the filing fee. A mark-up of the amended claims is contained in Appendix A hereto.

In the Specification:

Insert the abstract submitted herewith on a separate page.

CERTIFICATE OF MAILING
UNDER 37 C.F.R. 1.10

EXPRESS MAIL Mailing Label Number: EL 813789677 US
Date of Deposit: January 2, 2002

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, and/or fee, is being deposited with the United States Postal Service, "EXPRESS MAIL–POST OFFICE TO ADDRESSEE" service under 37 C.F.R. 1.10, on the date indicated above, and addressed to: Commissioner for Patents, Washington, D.C. 20231.

Signature of person mailing page:

Therese McKinley
Type or print name of person

In the Claims:

Rewrite claims 2, 4, 7, 9, 10, 14 and 15 to read as follows:

2. (amended) The sealant as claimed in Claim 1, wherein said dextran molecules include naturally occurring dextran, hydrophilic hydroxyl group-containing derivatives of dextran or modified forms of dextran containing other reactive groups.

4. (amended) The sealant as claimed in Claim 1 wherein the dextran molecules have a molecular weight of 30,000 to 60,000.

7. (amended) The method as claimed in Claim 6 wherein said flexible material is a polyester knitted or woven fabric, or a PTFE-based material.

9. (amended) The method as claimed in Claim 5 further including the step of plasticizing said cross-linked dextran by exposure of said coated surface to glycerol and, optionally, thereafter removing excess glycerol by alcohol rinsing.

10. (amended) A prosthetic graft impregnated or coated with the bioresorbable sealant as claimed in Claim 1 .

14. (amended) The method as claimed in Claim 11 wherein the temperature is from 30°C to 200°.

15. (amended) The method as claimed in Claim 11 wherein said dextran molecules have a molecular weight of 30,000 to 60,000.

Remarks

Claims 1-15 are pending in the application. The claims have been preliminarily amended to reduce dependencies and more closely conform to United States practice. The obvious

correction of "practising" to "*plasticizing*" has been made in claim 9. Support for the correction is found in the specification at page 7, lines 11-19.

The specification was amended in the international phase. A replacement page 3 is contained in the annex to the International Examination Report. It is understood that the replacement page will be inserted into the specification, and become part of the national stage specification.

Respectfully submitted,

KAREN ANNE KELSO



DANIEL A. MONACO
Registration No. 30,480
DRINKER BIDDLE & REATH LLP
One Logan Square
18th and Cherry Streets
Philadelphia, PA 19103-6996
Phone: (215) 988-3312
Fax: (215) 988-2757
Attorney for Applicant

APPENDIX A: Mark-up of amended claims

2. (amended) The sealant as claimed in Claim 1, wherein said dextran molecules include naturally occurring dextran, hydrophilic hydroxyl group-containing derivatives of dextran or modified forms of dextran containing other reactive groups[, for example dextran sulphate].

4. (amended) The sealant as claimed in [any one of Claims] Claim 1 [to 3] wherein the dextran molecules have a molecular weight of 30,000 to 60,000.

7. (amended) The method as claimed in [either one of Claims 5 and] Claim 6 wherein said flexible material is a polyester knitted or woven fabric, or a PTFE-based material.

9. (amended) The method as claimed in [any one of Claims] Claim 5 [to 8] further including the step of [practising] plasticizing said cross-lined dextran by exposure of said coated surface to glycerol and, optionally, thereafter removing excess glycerol by alcohol rinsing.

10. (amended) A prosthetic graft impregnated or coated with the bioresorbable sealant as claimed in [any one of Claims] Claim 1 [to 4].

14. (amended) The method as claimed in [any one of Claims] Claim 11 [to 13] wherein the temperature is from 30°C to 200°.

15. (amended) The method as claimed in [any one of Claims] Claim 11 [to 14] wherein said dextran molecules have a molecular weight of 30,000 to 60,000.

SEALANT FOR VASCULAR PROSTHESES

Abstract of the Disclosure

There is described a bioresorbable sealant or coating for a prosthetic graft. The novel sealant described is based upon dextran, preferably obtained by microbial fermentation, cross-linked through reaction with formaldehyde and urea. The breakdown products of the sealant or coating are all of low molecular weight and may be easily processed by the body. A method of producing the novel sealant or coating is also described.

SEALANT FOR VASCULAR PROSTHESES

The present invention relates to a non-gelatine based coating or sealant for porous vascular prostheses, and to a method of making that coating or sealant.

Porous vascular prostheses constructed from textiles (such as polyester) are normally woven or knitted and ultimately rely on host tissue penetrating into the spaces between the yarns. To function in the long term the prostheses must, therefore, acquire porosity whilst at implant bleeding through the prosthesis wall must be prevented or at least limited to an acceptable level.

In the past this dilemma has been resolved by soaking a porous textile-based prosthesis in the patient's blood which then clots to form a seal. This pre-clotting technique is time consuming, exposes the prosthesis to potential contamination and may be ineffective in patients with reduced clotting ability (either reduced

spontaneous blood clotting or through administration of anti-platelet or anti-thrombotic medication).

More recently, vascular prostheses have been pre-sealed with a variety of bioresorbable materials. The sealants tried to date have tended to be protein based, such as collagen, gelatin or albumen. Cross-linkers such as glutaraldehyde, formaldehyde, carbodiiamide or isocyanates have been used to render the proteins insoluble and mention may be made of EP-B-0,183,365; US-A-4,747,848 and US-A-4,902,290, all of which describe the preparation of cross-linked gelatin-based sealants. Hydrolysis or enzymatic attack in the host tissue has then gradually degraded or removed the sealant from the textile to permit the necessary tissue ingrowth.

The prior art protein based sealants are derived from animal or human sources, which creates the potential for transmission of infection. This has been especially of concern following transmission of BSE to humans which has greatly elevated public concern over the safety of animal derived implants. Additionally, although some materials, such as gelatin, are produced in large commercial quantities and blended to give high lot-to-lot consistency, manufacture from natural raw materials always has the potential for variability which creates uncertainty regarding performance of the graft.

The present invention relates to a bioresorbable sealant which is not animal derived but is based on

cross-linked dextran. Dextran is produced by a fermentation process using *Leuconostoc mesenteroides* bacteria growing on a sugar-based energy source, such as sucrose. Partial hydrolysis of the fermentation product yields dextrans of defined molecular weight. These have been used widely as plasma substitutes with a typical molecular weight of 40,000.

Dextrans of this molecular weight are freely water-soluble. To form a useful graft sealant, the dextrans must be rendered insoluble. However, dextrans are not easily cross-linked as they have limited reactive sites to form intermolecular bonds. The available groups are almost exclusively hydroxyl (OH) groups.

British Patent No 854,715 describes the formation of a dextran-based polymer by using epichlorohydrin. However the epichlorohydrin-based approach forms very stable cross-links so that the resultant polymer is resistant to both enzymatic and hydrolytic attack and does not biodegrade. Epichlorohydrin cross-linked dextran is, therefore, unsuitable as a vascular graft sealant as it is not bioresorbable and would not permit tissue ingrowth within the timescale required. EP-B-0,183,365 and US-A-4,747,848 both describe a gelatin-based sealant in which the time-scale of reabsorption is controllable.

To overcome this problem, a novel dextran-based polymer has been produced which is bioresorbable through hydrolysis in the time scale of interest.

The present invention provides a bioresorbable sealant composition comprising a polymer formed by reaction between dextran, formaldehyde and urea. Whilst the dextran polymer product is insoluble, the polymer is formed with bonds that are sufficiently labile to permit resorption at an appropriate rate for tissue ingrowth. Furthermore, when the cross-linked polymer breaks down, it does so into simple products all of which have a low molecular weight and which are easy for the body to dispose of.

The term "dextran" as used herein includes naturally occurring dextran (especially that obtained through fermentation of micro-organisms such as *Leuconostoc sp.*) as well as hydrophilic hydroxyl group-containing derivatives of dextran, for example partially depolymerized dextran, dextran glycerine glycoside or hydrodextran. Also included are modified forms of dextran containing other reactive groups, for example carboxyl, sulphonic, sulphate, amino or substituted amino groups. Mention may be made of carboxymethyldextran and dextran sulphate as examples of modified dextran. Mixtures of different dextrans (as defined herein) may of course also be used, where appropriate.

The polymer described herein is formed in water or an aqueous-based solvent. It is therefore essential that the dextran selected as the initial reactant should be water-soluble or in the form of swollen particles.

Dextrans having a molecular weight of 10,000 to 100,000, in particular 20,000 to 80,000, especially 30,000 to 60,000 may be used. Preferably the dextran used in the invention has a typical molecular weight of about 40,000.

Viewed from one aspect, therefore, the present invention provides a method of forming polymerised dextran for use as a biodegradable coating for a prosthetic graft, said method comprising:

a) exposing a water-based solution of dextran to 2 to 25 (weight %) of urea and allowing the urea to enter into solution to form a mixture;

b) exposing the mixture of step a) to formaldehyde;

c) heating the mixture of step b) at temperatures between 20 to 250°C for a time sufficient to allow polymerisation to occur.

The formaldehyde is conveniently added in the form of formalin (a 37% aqueous solution of formaldehyde hydrate). Alternatively, it would be possible to bubble formaldehyde gas through the mixture of step (a) to achieve the required reaction. The quantity of formaldehyde required may be determined stochiometrically having regard to the amount of urea added in step (a). We have found that an amount of formaldehyde equivalent to 50 to 100% (by weight) with reference to the amount of urea achieves the required

result, with 70 to 80% (by weight) being preferred. Usually a time period of from five to 60 minutes is sufficient to permit the cross-linking reaction to occur.

In a further aspect, the present invention provides a method of producing a non-porous graft by impregnating or coating a flexible material with a mixture of dextran, urea and formaldehyde, and incubating said impregnated material at temperatures of from 20°C to 250°C for a time sufficient to facilitate cross-linking of said dextran. The flexible material to be impregnated or coated will usually be a macroporous (eg a knitted or woven) fabric. However, non-porous or microporous materials may likewise be coated, with the sealant reducing blood loss after suturing.

Preferably the temperature selected is from 30°C to 200°C, for example is from 45°C to 160°C.

The flexible porous material to be treated by the present invention may be of any conventional type or construction. Particular mention may be made of polyester (e.g. DACRON™) knitted or woven fabric and also of PTFE-based materials. Additionally, expanded PTFE may be coated as described since, although the material itself is non-porous, porosity will be introduced when the graft is stitched into place by the surgeon. The graft may be simply immersed in the reaction mixture or may be selectively dipped therein (for example the graft may be placed on a mandrel and

"rolled" over the surface of the reaction mixture to coat the external surface only). Optionally pressure may be used to ensure penetration of the reaction mixture into the interstices of a porous graft.

In a further aspect, the invention also provides a prosthetic graft impregnated or coated with the bioresorbable sealant of the invention. The graft may be, for example, a knitted polyester graft.

To prevent the sealant from drying out on the graft and becoming brittle in storage it is advantageous to plasticise the treated graft with a biocompatible agent such as glycerol. This is preferably achieved by treating the sealed grafts with glycerol after cross-linking of the dextran. Excess glycerol may be removed by alcohol rinsing. Suitable alcohols include ethanol, methanol and propanol, but other alcohols may also be used.

As described above, the treated graft may be plasticised. Alternatively, or additionally, the graft may undergo a separate sterilisation step, for example by exposure to γ-irradiation. Sterilisation may not be required if the graft and coating have been formed in sterile conditions.

The primary mechanism of polymerisation involves a urea/formaldehyde condensation reaction, where the application of high temperature and water encourages polymerisation of the dextran reactant. Subsequent

condensation reactions involve primary hydroxyl groups present on the dextran molecule. Due to the small levels of urea and formaldehyde required to cause the reactions it was believed the process needed only short urea-formaldehyde condensate links to give good cross-linking parameters. Subsequently formed bonds were identified as reactive ether bonds which were subject to hydrolytic degradation. Various forms of analysis such as NMR and FTIR have confirmed that the degradation products are of low molecular weight and likely to comprise sugar units, urea, formaldehyde and small complexes of the latter components. It is of course possible to modify the hydroxyl groups available on the dextran for reaction (see for example EP-B-0,183,365).

The use of dextran sulphate is desirable since the cross-linked polymer so produced contains sulphate groups available for binding, for example, to the heparin binding site of fibroblast growth factor. Fibroblast growth factors form a large family of structurally related, multifunctional proteins that regulate various biological responses and have been implicated in many developmental and regenerative events including axial organisation, mesodermal patterning, keratinocyte organisation and brain development. These compounds mediate cellular functions by binding to transmembrane fibroblast growth factor receptors, which are protein tyrosine kinases. Fibroblast growth factor receptors are activated by oligomerisation and both this activation and fibroblast growth factor stimulated biological responses, require

the presence of "heparin-like" molecules as well as fibroblast growth factor.

Heparins are linear polysaccharide chains; they are typically heterogeneously sulphated on alternating L-iduronic and D-glycosamino sugars. A review of the fibroblast growth factor molecular complexes associated with heparin-like sugars has recently been undertaken (DiGabriele et al., 1998; ISSN 0028-0836). Heparin sulphates, the N-sulphated polysaccharide components of proteoglycans, are common constituents of cell surfaces and the extracellular matrix. The heparin sulphate polysaccharide chain has a unique molecular design in which the clusters of N and O-sulphated sugar residues, separated by regions of low sulphation, determine specific protein binding properties. Current data indicates that relatively long specific binding sequences of heparin sulphate may induce a conformational change in basic fibroblast growth factor, exposing a site on the protein that is recognised by signal transducing receptors. There are also suggestions that the core protein of plasma membrane heparin sulphate-proteoglycans may participate in the cell signalling process (Gallagher, 1994; ISSN 0939-4974).

The heparin sulphate chains are attached to various protein cores, which determine the location of the proteoglycan in the cell membrane and extracellular matrix. The diverse functions of heparin sulphate, which range from the control of blood coagulation to the regulation of cell growth and adhesion, depend on

the capacity of the chains to activate protein ligands, such as antithrombin III and members of the fibroblast growth factor family. These properties are currently being exploited in the development of synthetic heparin sulphates as anticoagulants and promoters of wound healing. Conversely organic mimics of growth factor-activating saccharides could possibly be designed to suppress tumour growth and prevent restenosis after coronary vessel angioplasty (Stringer and Gallagher, 1997; ISSN 1357-2725). Earlier researchers had also reported on the theory that fibroblast growth factor receptors might be directly activated by a much wider range of ligands, including heparin sulphate proteoglycans and neural cell adhesion molecules as well as related sulphonated compounds (Green et al., 1996; ISSN 0265-9247). As early as 1994 research groups were investigating areas which would aid the design of synthetic sulphonated oligosaccharides aimed at improving the bioavailability of fibroblast growth factor when administered *in vivo* as a therapeutic agent (Coltrini et al., 1994; ISSN 0264-6021). Thus, Belford et al (1993) in Journal of Cellular Physiology 157 : 184-189 describes the ability of several animal, plant and bacterial derived polyanions as well as synthetic polyanions to compete with heparin for the binding of acidic fibroblast growth factor and correlates this with their ability to potentiate the mitogenic and neurotrophic actions of this factor. Dextran sulphate, kappa-carrageenan, pentosan sulphate, polyanethole sulphonate, heparin and fucoidin were shown to compete for the heparin binding site on a fibroblast growth

factor at relatively low concentrations (<50 μg/ml). The differential effects of these polyanions in potentiating the biological activities of fibroblast growth factor in relation to their ability to compete for the heparin-binding site of a fibroblast growth factor is discussed. Similarly, Hoover et al (1980) (in Circulation Research 47: 578: 583) studied the in vitro effects of heparin on the growth of rat aortic smooth muscle cells. The results showed that there was a highly specific interaction with regard to molecule and cell type i.e. other polyanions. The suggestion was that heparin and related dextran sulphate could in some way bind to certain factors responsible for cell growth and subsequent proliferation.

Non-enzymic glycosylation of basic fibroblast growth factor has recently been demonstrated to decrease the mitogenic activity of intracellular basic fibroblast growth factor. Loss of this bioactivity has been implicated in impaired wound healing and microangiopathics of diabetes mellitus. In addition to intracellular localisation, basic fibroblast growth factor is widely distributed in the extracellular matrix, primarily bound to heparin sulphate proteoglycans. Nissen et al (1999) measured the effect of non-enzymic glycosylation on basic fibroblast growth factor bound to heparin, heparin sulphate and related compounds (see Biochemical Journal 338: 637-642). When heparin was added to basic fibroblast growth factor prior to non-enzymic glycosylation, the mitogenic activity and heparin affinity of basic fibroblast

growth factor were nearly completely preserved. Heparin sulphate, low molecular mass heparin and the polysaccharide, dextran sulphate, demonstrated a similar protective effect.

The invention is now further described by reference to the following, non-limiting, examples (together with a comparative example).

Example 1

90 ml of water was added to 50 g of 40,000 molecular weight dextran and manually mixed to encourage the dextran to enter into solution. Afterwards the mixture was placed on a magnetic stirrer and allowed to mix continuously for 15 minutes or until the solution was clear and particle free.

5 g of urea were then added to the solubilised dextran and the mixture placed back on the magnetic stirrer for a further 15 minutes to ensure that the urea had entered into solution with the dextran. Finally, 10 ml of formalin (a 38% (w/v) aqueous solution of formaldehyde hydrate) providing 3.8 g of formaldehyde was added to complete the mixture which was again allowed to stir for 15 minutes. This mixture was the impregnated into knitted polyester grafts using vacuum techniques.

Gels were formed by placing the dextran impregnated grafts in an oven at 150°C for 2 hours. During this

time a cross-linking reaction was taking place. Grafts were washed for a minimum of four hours to ensure removal of any residual formaldehyde. Finished grafts were softened by exposure to 100% glycerol for 10 minutes followed by an alcohol wash to remove any excess glycerol. Grafts were then left to air dry.

Example 2

92 ml of water was added to 40 g of 40,000 molecular weight dextran and manually mixed to encourage the dextran to enter into solution. Afterwards, the mixture was placed on a magnetic stirrer and allowed to mix continuously for 15 minutes or until the solution was clear and particle free.

4 g of urea were then added to the solubilised dextran and the mixture placed back on the magnetic stirrer for a further 15 minutes to ensure that the urea had entered into solution with the dextran. Finally, 8 ml of formalin (38% aqueous solution of formaldehyde hydrate) providing 3.04 g formaldehyde was added to complete the mixture which was again allowed to stir for 15 minutes. Knitted polyester grafts were vacuum impregnated with this mixture.

Gels were formed by placing the grafts in an oven at 50°C for 12 hours. During this time a cross-linking reaction was taking place. Grafts were washed for a minimum of four hours to ensure removal of any residual formaldehyde. Finished grafts were softened by

exposure to 80% (v/v, in water) glycerol for 10 minutes followed by an alcohol wash to remove any excess glycerol. Grafts were then left to air dry.

Example 3 - Preparation of Dextran Blends

Table 1: Dextran/dextran sulphate crosslinked blends

Dextran (g)	Dextran Sulphate (g)	Urea (g)	Formaldehyde (ml)	Water (ml)
10	0	1	2	18
9	1	1	2	18
8	2	1	2	18
7	3	1	2	18
6	4	1	2	18
5	5	1	2	18

Dextran of molecular weigh 40,000 was weighed and the corresponding weight of dextran sulphate of similar molecular weight were added together. The correct level of water was added and the substances mixed thorougly until clear. The urea was mixed again before final addition of formaldehyde. The completed preparation was further mixed to ensure complete solubilisation. Gels were formed when the completed mix was placed in an oven for a specified time period. Samples were then washed for 3 hours in continuous running water.

Corresponding analysis (Dionex ion chromatography) to investigate the presence of sulphate groups in each of the samples showed significant detection of sulphation,

with least levels present in sample 1 (1 g of dextran sulphate) and most in sample 5 (5 g of dextran sulphate). It was proposed that the dextran sulphate had become entrapped within the network of cross-linked dextran chains to form an interpenetrating network with the potential to offer corresponding sulphation to the gels for subsequent attachment of growth factors. From the results various sulphanated gels could be prepared, see Examples 4 to 7.

Example 4

90 ml of water was added to a mixture of 30 g of 40,000 molecular weight dextran and 20 g of 40,000 molecular weight dextran sulphate and manually mixed to encourage the two forms of dextran to enter into solution with each other. Afterwards, the mixture was placed on a magnetic stirrer and allowed to mix continuously for 15 minutes or until the solution was clear and particle free.

5 g of urea was added and the mixture placed back on the magnetic stirrer for a further 15 minutes to ensure that the urea had entered into solution with the two dextran species. Finally, 10 ml of formaldehyde was added to complete the mixture, which was again allowed to stir for 15 minutes.

Gels were formed by placing the dextran mixture into an oven at 50°C for a minimum of 12 hours. During this time, a cross-linking reaction took place. The

subsequent dextran mixtures were washed for a minimum of 3 hours under continuous running water.

Example 5

90 ml of water was added to a mixture of 25 g of 40,000 molecular weight dextran and 25 g of 40,000 molecular weight dextran sulphate and manually mixed to encourage the two forms of dextran to enter into solution with each other. Afterwards the mixture was placed on a magnetic stirrer and allowed to mix continuously for 15 minutes or until the solution was clear and particle free.

5 g of urea was added and the mixture was placed back on the magnetic stirrer for a further 15 minutes to ensure that the urea had entered into solution with the two dextran species. Finally, 10 ml of formaldehyde was added to complete the mixture, which was again allowed to stir for 15 minutes.

Gels were formed by placing the dextran mixture into an oven at 50°C for a minimum of 12 hours. During this time a cross-linking reaction took place. The subsequent dextran mixtures were washed for a minimum of 3 hours under continuous running water.

Example 6

90 ml of water was added to a mixture of 30 g of 40,000 molecular weight dextran and 20 g of 40,000 molecular weight dextran sulphate and manually mixed to encourage

the two forms of dextran to enter into solution with each other. Afterwards the mixture was placed on a magnetic stirrer and allowed to mix continuously for 15 minutes or until the solution was clear and particle free.

5 g of urea was added and the mixture placed back on the magnetic stirrer for a further 15 minutes to ensure that the urea had entered into solution with the two dextran species. Finally, 10 ml of formaldehyde was added to complete the mixture, which was again allowed to stir for 15 minutes.

Gels were formed by placing the dextran mixture into an oven at 100°C for a minimum of 2 hours. During this time a cross-linking reaction took place. The subsequent dextran mixtures were washed for a minimum of 3 hours under continuos running water.

Example 7

90 ml of water was added to a mixture of 25 g of 40,000 molecular weight dextran and 25 g of 40,000 molecular weight dextran sulphate and manually mixed to encourage the two forms of dextran to enter into solution with each other. Afterwards the mixture was placed on a magnetic stirrer and allowed to mix continuously for 15 minutes or until the solution was clear and particle free.

5 g of urea was added and the mixture placed back on the magnetic stirrer for a further 15 minutes to ensure that the urea had entered into solution with the two dextran species. Finally, 10 ml of formaldehyde was added to complete the mixture, which was again allowed to stir for 15 minutes.

Gels were formed by placing the dextran mixture into an oven at 100°C for a minimum of 2 hours. During this time a cross-linking reaction took place. The subsequent dextran mixtures were washed for a minimum of 3 hours under continuos running water.

Example 8 - Resorption Rates

The resorption rate of sealant from dextran sealed grafts made according to Examples 1 and 2 were determined *in vitro* by incubating graft samples of known weight in buffer and weighing the grafts again after drying to measure the amount of sealant remaining. Urea formaldehyde cross-linked dextran was found to be hydrolysed at a rate comparable to the gelatin sealant of EP-B-0,183,365.

The hydrolysis profiles of urea-formaldehyde cross-linked dextran and formaldehyde cross-linked gelatin grafts are detailed in Table 2. Hydrolysis was performed at 37°C over a period of up to 4 weeks at 125 rpm.

Table 2

Comparative hydrolysis results for dextran and gelatin coated vascular grafts. The gelatin coated grafts were produced in accordance with Example 1 of EP-B-0,183,365.

Day	% gel degraded	
	Dextran	Gelatin*
0	0	0
3	5	30
6	15	70
12	25	95
28	95	100

*Comparative Example

Example 9 - Implantation

Grafts prepared according to Example 1 were implanted into the abdominal aorta of dogs for 2 weeks and 4 weeks respectively. Histological examination of the explanted devices showed that the sealant was resorbed as expected within 1 month and that the normal healing process was not adversely affected.

Claims

1 A bioresorbable sealant composition for coating a prosthetic graft, said composition comprising a polymer formed by cross-linking dextran molecules by formaldehyde and urea condensation.

2 The sealant as claimed in Claim 1, wherein said dextran molecules include naturally occurring dextran, hydrophilic hydroxyl group-containing derivatives of dextran or modified forms of dextran containing other reactive groups, for example dextran sulphate.

3 The sealant as claimed in Claim 1, wherein said naturally occurring dextran is provided by fermentation using *Leuconostoc mesenteroides* bacteria.

4 The sealant as claimed in any one of Claims 1 to 3 wherein the dextran molecules have a molecular weight of 30,000 to 60,000.

5 A method of producing a substantially non-porous graft by exposing at least one surface of a flexible material to a mixture of dextran, urea and formaldehyde, and incubating at temperatures of from 20°C to 250°C for a time sufficient for cross-linking of said dextran on said surface to take place.

6 The method as claimed in Claim 5 wherein the temperature is from 30°C to 200°C.

7 The method as claimed in either one of Claims 5 and 6 wherein said flexible material is a polyester knitted or woven fabric, or a PTFE-based material.

8 The method as claimed in Claim 7 wherein said fabric material is expanded PTFE.

9 The method as claimed in any one of Claims 5 to 8 further including the step of practising said cross-linked dextran by exposure of said coated surface to glycerol and, optionally, thereafter removing excess glycerol by alcohol rinsing.

10 A prosthetic graft impregnated or coated with the bioresorbable sealant as claimed in any one of Claims 1 to 4.

11 A method of forming polymerised dextran for use as a biodegradable coating for a prosthetic graft, said method comprising:

a) exposing a water-based solution of dextran to 2 to 25 (weight %) of urea and allowing the urea to enter into solution to form a mixture;

b) exposing the mixture of step a) to formaldehyde;

c) heating the mixture of step b) at temperatures between 20 to 250°C for a time sufficient to allow polymerisation to occur.

12 The method as claimed in Claim 11 wherein 50 to 100% (by weight) of formaldehyde, by reference to the weight of urea, is added.

13 The method as claimed in Claim 12 wherein 70 to 80% (be weight) of formaldehyde, by reference to the weight of urea, is added.

14 The method as claimed in any one of Claims 11 to 13 wherein the temperature is from 30°C to 200°C.

15 The method as claimed in any one of Claims 11 to 14 wherein said dextran has a molecular weight of 30,000 to 60,000.

United States Patent Application

COMBINED DECLARATION AND POWER OF ATTORNEY

Attorney's Docket Number _____

As a below named inventor, I hereby declare that:
My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled:

"Sealant for Vascular Prostheses"

the specification of which:

[c] was filed as a PCT International Application Number PCT/GB00/03343 on 1 September 2000.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with 37 CFR §1.56.

I hereby claim foreign priority documents under 35 U.S.C §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT international application which designated at least one country other than the United States, listed below and have also identified below any foreign application for patent or inventor's certificate or PCT international application having a filing date before that of the application on which priority is claimed:

PRIOR FOREIGN/PCT APPLICATION(S)

COUNTRY	APPLICATION NUMBER	DATE OF FILING	PRIORITY CLAIMED
GB	9920732.6	3 September 1999	YES

I hereby claim the benefit under 35 U.S.C §120 of any United States application(s) or §365(c) of any PCT international application(s) designating the United States, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of 35 U.S.C. §112, I acknowledge the duty to disclose material information as defined in 37 CFR §1.56 which become available between the filing date of the prior application and the national or PCT international filing date of this application:

PRIOR US APPLICATIONS OR PCT INTERNATIONAL APPLICATIONS DESIGNATING THE US FOR BENEFIT UNDER 25 U.S.C §120

APPLICATION No.	DATE OF FILING	PATENTED	PENDING	ABANDONED

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following attorney(s) and/or agent(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith:

Drinker, Biddle & Reath LLP
One Logan Square
18th & Cherry Streets
Philadelphia
PA 19103-6996
USA

Arthur H. Seidel - Registration No 15,979
Daniel A. Monaco - Registration No 30,480
John J. Marshall - Registration No 39,671
Robert E. Cannuscio – Registration No 36,469
Gregory J. Lavorgna - Registration No 30,469
Thomas J. Durling - Registration No 31,349
Joseph R. Delmaster - Registration No 38,399

I acknowledge the duty to disclose information which is material to the examination of this Application in accordance with Title 37, Code of Federal Regulations, Section 1.56(a).

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on the information and belief are believed to be true; and further that these statements were made with the knowledge that wilful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such wilful false statements may jeopardize the validity of the Application or any Patent issuing thereon.

INVENTOR

Full Name:	KELSO, Karen Anne
Residence:	Kilmarnock, Scotland
Citizenship:	British, (Great Britain) GBN
Post Office Address:	4 Dalgarven Mews, Kilmarnock, KA3 6BJ, United Kingdom

Signature of Inventor Karen Kelso Date 29-11-01